TRP-2 T cells

**TRP-2 T cells** are a form of adoptive T cell therapy consisting of T lymphocytes engineered or selected to recognize tyrosinase-related protein 2 (TRP-2, also known as dopachrome tautomerase or DCT), a melanocyte differentiation antigen overexpressed in melanoma cells. These T cells are most commonly CD8+ cytotoxic T lymphocytes (CTLs) with T cell receptors (TCRs) specific for the TRP-2(180-188) epitope, enabling them to target and kill TRP-2-expressing melanoma cells. Their mechanism of action relies on TCR-mediated recognition of TRP-2 peptide presented on MHC class I molecules, triggering immune-mediated tumor cell destruction. Preclinical models using transgenic mice expressing a TRP-2-specific TCR have shown TRP-2 T cells can proliferate in response to antigen, infiltrate melanoma tumors (e.g., B16 model), and in some settings reduce pulmonary melanoma metastases—though antitumor efficacy may be limited by the tumor microenvironment and immune tolerance mechanisms. TRP-2 T cells have been developed and studied primarily for melanoma immunotherapy, serving as a model for antigen-specific TCR-based adoptive cell transfer[1][3].

Other names

TRP-2-specific T cellsTRP2-specific T cellsTRP 2-specific T cellsTyrosinase-related protein 2-specific T cellsTRP-2 CD8+ T cells